See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Donald Trump
Vladimir Putin
Elon Musk
Israel-Hamas Conflict
Basketball
Premier League
Immigration
CPAC
Vatican
Wrestling
Baseball
Published • loading... • Updated

First US patient dosed in Phase 1b trial of CF therapy RCT2100

Summary by Cystic Fibrosis News Today
A Phase 1b trial assessing the safety of inhaled therapy RCT2100 in cystic fibrosis patients has dosed the first participant in the U.S.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Cystic Fibrosis News TodayCystic Fibrosis News Today

First US patient dosed in Phase 1b trial of CF therapy RCT2100

A Phase 1b trial assessing the safety of inhaled therapy RCT2100 in cystic fibrosis patients has dosed the first participant in the U.S.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Cystic Fibrosis News Today broke the news in on Monday, January 13, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Valhalla

Valhalla

News
For You
Search
BlindspotLocal